# Avatrombopag vs. Placebo for CIT in GI Malignancies

> **NCT05772546** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hanny Al-Samkari, MD** · enrollment: 60 (estimated)

## Conditions studied

- Gastrointestinal Cancer
- Gastrointestinal Neoplasms
- Chemotherapy-Induced Thrombocytopenia

## Interventions

- **DRUG:** Avatrombopag
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05772546
- **Lead sponsor:** Hanny Al-Samkari, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-01-02
- **Final completion:** 2026-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05772546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05772546, "Avatrombopag vs. Placebo for CIT in GI Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05772546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*